Fig. 5From: A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccineIn vivo study showing the tumor treatment effect and the generation of memory T cells by the DC-based cancer vaccine using RPS3 as adjuvantBack to article page